Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 6 January 2026 - 8 January 2026

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros Corp shares rose about 4% to $14.09 premarket after setting a $36,000 price for each vial of newly approved Yartemlea, used to treat TA-TMA in transplant patients. The company began its U.S. launch Jan. 2 and reported $171.5 million in cash at year-end. Shares jumped 6.6% in after-hours trading Wednesday. Analysts raised price targets following the announcement.
8 January 2026
··
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie shares fell 1.6% to $229.64 premarket after the company denied talks to acquire Revolution Medicines and cut its 2025 profit forecast. Revolution stock dropped 11.5% following AbbVie’s statement. AbbVie now expects 2025 adjusted EPS of $9.90 to $9.94, down from its previous outlook, citing a $1.3 billion acquired IPR&D charge. Earnings are due Feb. 4.
8 January 2026
···
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie shares fell 1% to $231.11 in after-hours trading after the company denied reports of takeover talks with Revolution Medicines. A new SEC filing flagged a $1.3 billion fourth-quarter charge, prompting AbbVie to cut its 2025 adjusted earnings forecast to $9.90–$9.94 per share from $10.61–$10.65. Revolution shares dropped 11.5% late.
8 January 2026
····
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

Eli Lilly shares rose 4.1% to $1,108.09 after the company agreed to acquire Ventyx Biosciences for $1.2 billion in cash. Ventyx holders will receive $14 per share, a 62% premium to its 30-day VWAP. The deal is expected to close in the first half of 2026, pending regulatory and shareholder approval. Lilly also announced a multi-year obesity drug partnership with Nimbus Therapeutics.
7 January 2026
···
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna shares fell 1.4% to $35.15 premarket Wednesday after a 10.9% surge Tuesday, following news it filed for approval of its mRNA flu vaccine in the U.S., Europe, Canada, and Australia. The company reported 26.6% relative efficacy for the vaccine in adults 50 and older. Bayer’s Monsanto unit sued Moderna and other COVID-19 vaccine makers Tuesday, alleging mRNA patent infringement.
7 January 2026
··
GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

GSK said its hepatitis B drug bepirovirsen met primary endpoints in two phase III trials, with global filings planned from early 2026. Shares closed up 4.3% after the news. The European Commission approved a new syringe format for Shingrix, and Japan cleared Exdensur for severe asthma. Investors await full phase III data on bepirovirsen’s durability and safety before sales impact is clear.
7 January 2026
··
Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Merck shares rose 1.1% to $108.60 Tuesday, hitting a 52-week high of $110.16 amid investor focus on U.S. vaccine schedule changes and upcoming CEO remarks at the J.P. Morgan Healthcare Conference Jan. 12. The company’s Gardasil HPV vaccine faces uncertainty after the CDC shifted to a single-dose recommendation, while an FDA decision on Keytruda in ovarian cancer is expected Feb. 20.
6 January 2026
··
Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson shares rose 0.5% to $205.41 midday Tuesday after reporting positive Phase 2b results for its lupus drug nipocalimab and announcing plans for Phase 3 trials. The company also filed in Europe to expand use of its myeloma drug combo Tecvayli and Darzalex. J&J continues to face pressure from ongoing talc litigation, with more trials expected this year.
6 January 2026
···
1 … 16 17 18 19 20 … 38

Stock Market Today

  • XRP Rises as Japan Classifies Token as Financial Asset, Boosting Market Sentiment
    April 11, 2026, 11:29 AM EDT. Ripple's XRP gained to $1.35 after Japan's cabinet approved a bill classifying the token as a financial instrument under the Financial Instruments and Exchange Act. This regulatory clarity, set to take effect in fiscal 2027, reduces legal uncertainty for Japanese banks-over 80% of which connect with Ripple's network-and fuels investor optimism. XRP's market cap stood at $82.6 billion with a 26% drop in trading volume to $1.77 billion over 24 hours. Positive sentiment is also driven by potential U.S. regulatory progress with the CLARITY Act, expected in late April, which could facilitate inflows into crypto ETFs. Technical analysts point to cautious bullish momentum, with short-term trading between $1.30 and $1.40, and longer-term targets suggesting substantial upside. These developments position XRP for stronger institutional use and growth in cross-border payments.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 11:42 AM EDT XRP Rises as Japan Classifies Token as Financial Asset, Boosting Market Sentiment April 11, 2026, 11:29 AM EDT. Ripple's XRP gained to $1.35 after Japan's cabinet approved a bill classifying the token as a financial instrument under the Financial Instruments and Exchange Act. This regulatory clarity, set to take effect in fiscal 2027, reduces legal uncertainty for Japanese banks-over 80% of which connect with Ripple's network-and fuels investor optimism. XRP's market cap stood at $82.6 billion with a 26% drop in trading volume to $1.77
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop